10-Q: Hestia Insight Inc. Reports Strong Revenue Growth in Q3 2024, But Internal Control Weaknesses Persist

Hestia Insight Inc. saw a significant increase in revenue and a return to profitability in the third quarter of 2024, but also reported ongoing issues with internal controls.

Summary

• Hestia Insight Inc. reported a substantial increase in revenue for the nine months ended August 31, 2024, reaching $1,312,930, compared to $75,500 for the same period in 2023.
• The company achieved a net income of $713,103 for the nine months ended August 31, 2024, a significant turnaround from a net loss of $425,363 in the same period of the previous year.
• Operating expenses decreased to $189,056 for the nine months ended August 31, 2024, down from $324,987 in the same period of 2023, primarily due to reduced professional fees.
• The company's cash balance decreased to $56,633 as of August 31, 2024, from $93,890 at the end of November 2023.
• Hestia Insight Inc. reported a related party note payable of $78,931 as of August 31, 2024.
• The company issued stock options to its Chairman and a director, totaling 1,500,000 shares, with an exercise price of $0.20 per share.
• The company acknowledged that its disclosure controls and procedures were ineffective as of August 31, 2024, due to limited resources and employees.

Sentiment

Score: 6

Explanation: The document shows a significant improvement in revenue and profitability, which is positive. However, the company's weak internal controls, dependence on external financing, and reduced cash balance temper the overall sentiment.

Positives

• The company experienced a significant increase in revenue, indicating strong growth in its consulting business.
• Hestia Insight Inc. returned to profitability, demonstrating improved financial performance.
• Operating expenses were reduced, contributing to the improved bottom line.
• The company secured a related party loan of $78,931, providing additional capital.

Negatives

• The company's cash balance decreased, raising concerns about liquidity.
• The company reported ineffective disclosure controls and procedures, indicating potential risks in financial reporting.
• The company has an accumulated deficit of $43,425 as of August 31, 2024.
• The company is dependent on debt and equity financing to fund its operations.

Risks

• The company's limited operating history and dependence on external financing pose a risk to its long-term viability.
• The ineffective disclosure controls and procedures could lead to inaccurate financial reporting and potential regulatory issues.
• The company's ability to continue as a going concern is dependent on its ability to generate revenue and secure additional financing.
• The company faces competition in its consulting business and may struggle to maintain its competitive advantage.
• The company's reliance on a small number of employees and independent contractors could create operational challenges.

Future Outlook

The company's future growth is dependent on its ability to continue providing medical consulting services, generate revenue, and obtain additional financing. The company plans to pursue acquisitions and joint ventures in the healthcare and biotech sectors.

Management Comments

• Management believes that it will be successful in its capital formation and planned operating activities.
• Management is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• Management concluded that our disclosure controls and procedures were ineffective as of August 31, 2024.

Industry Context

The company operates in the healthcare and biotech sectors, which are highly regulated and subject to rapid change. The company's consulting services compete with a variety of advisory firms and other organizations. The company is also involved in the smart vending machine industry, which is a growing market.

Comparison to Industry Standards

• The company's revenue growth is significant compared to its previous performance, but it is difficult to compare to industry standards without more specific information on its niche market.
• The return to profitability is a positive sign, but the company's small size and limited operating history make it difficult to compare to larger, established companies in the healthcare and biotech sectors.
• The company's reliance on related party loans is not uncommon for small companies, but it is important to monitor the terms and conditions of these loans.
• The reported weakness in internal controls is a concern and should be addressed to meet industry standards for financial reporting.

Related Party Transactions

• The company entered into a $50,000 note payable with ECL Capital Partners Corp, a related party, on January 15, 2024.
• An additional loan of $3,930.91 was received from Mr. Edward C. Lee, a related party, as a short-term loan.
• The company entered into a $50,000 note payable with ECL Capital Partners Corp, a related party, on August 25, 2024.

Stakeholder Impact

• Shareholders will be encouraged by the improved financial performance, but should be aware of the risks associated with the company's weak internal controls and dependence on external financing.
• Employees may benefit from the company's growth, but should be aware of the potential risks to the company's long-term viability.
• Customers may benefit from the company's expanded services and offerings.
• Creditors should be aware of the company's dependence on external financing and its reduced cash balance.

Next Steps

• The company intends to pursue the acquisition and development of healthcare related technologies.
• The company will continue to seek opportunities for joint ventures and strategic relationships.
• The company needs to address the identified weaknesses in its internal controls and procedures.

Key Dates

Keywords

consulting, healthcare, biotech, revenue, profitability, financial results, stock options, internal controls, related party loan, vending machines